Ascletis Pharma Inc - Asset Resilience Ratio

Latest as of December 2025: 22.13%

Ascletis Pharma Inc (2VJ) has an Asset Resilience Ratio of 22.13% as of December 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See working capital to net assets of Ascletis Pharma Inc to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

€457.36 Million

≈ $534.70 Million USD Cash + Short-term Investments

Total Assets

€2.07 Billion

≈ $2.42 Billion USD All company assets

Resilience Assessment

Good

Financial Resilience Level

Asset Resilience Ratio Trend (2016–2025)

This chart shows how Ascletis Pharma Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see total assets of Ascletis Pharma Inc.

Liquid Assets Composition Over Time

This chart breaks down Ascletis Pharma Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Read total liabilities of Ascletis Pharma Inc for a breakdown of total debt and financial obligations.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	€0.00	0%
Short-term Investments	€457.36 Million	22.13%
Total Liquid Assets	€457.36 Million	22.13%

Asset Resilience Insights

Good Liquidity Position: Ascletis Pharma Inc maintains a healthy 22.13% of assets in liquid form.
This level provides good financial flexibility while maintaining productive asset deployment.
The company has significant short-term investments, indicating active treasury management.

Ascletis Pharma Inc Industry Peers by Asset Resilience Ratio

Compare Ascletis Pharma Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Ligand Pharmaceuticals Incorporated NASDAQ:LGND	Biotechnology	16.06%
Genscript Biotech Corporation F:G51	Biotechnology	13.79%
Xiamen Amoytop Biotech Co Ltd SHG:688278	Biotechnology	4.69%
BB Biotech AG SW:BION	Biotechnology	92.97%
89bio Inc NASDAQ:ETNB	Biotechnology	71.60%
Pacific Shuanglin Bio pharmacy Co Ltd SHE:000403	Biotechnology	2.66%
Vor Biopharma Inc NASDAQ:VOR	Biotechnology	74.48%

Annual Asset Resilience Ratio for Ascletis Pharma Inc (2016–2025)

The table below shows the annual Asset Resilience Ratio data for Ascletis Pharma Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-12-31	22.13%	€457.36 Million ≈ $534.70 Million	€2.07 Billion ≈ $2.42 Billion	-28.79pp
2024-12-31	50.92%	€1.08 Billion ≈ $1.26 Billion	€2.12 Billion ≈ $2.48 Billion	-28.14pp
2023-12-31	79.06%	€1.97 Billion ≈ $2.30 Billion	€2.49 Billion ≈ $2.91 Billion	+78.63pp
2022-12-31	0.42%	€11.20 Million ≈ $13.09 Million	€2.66 Billion ≈ $3.11 Billion	+0.24pp
2021-12-31	0.18%	€5.20 Million ≈ $6.08 Million	€2.83 Billion ≈ $3.31 Billion	-14.33pp
2017-12-31	14.51%	€143.83 Million ≈ $168.15 Million	€991.25 Million ≈ $1.16 Billion	+13.46pp
2016-12-31	1.05%	€5.61 Million ≈ $6.56 Million	€536.26 Million ≈ $626.95 Million	--

pp = percentage points

About Ascletis Pharma Inc

F:2VJ Germany Biotechnology

Market Cap

$1.20 Billion

€1.02 Billion EUR

Market Cap Rank

#8195 Global

#1085 in Germany

Share Price

€0.97

Change (1 day)

+10.23%

52-Week Range

€0.88 - €1.99

All Time High

€1.99